{"schema_version":"secwatch.filing_event.v1","accession":"0001224608-23-000067","form_type":"8-K","ticker":"CNO","cik":"0001224608","company_name":"CNO Financial Group, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.457958+00:00","generated_at":"2026-06-08T04:39:32.090608+00:00","sec_items":["1.01","3.03","5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CNO extends CEO Bhojwani's contract to 2028 and renews poison pill through 2026","bullets":["CEO Gary C. Bhojwani employment term extended to April 1, 2028 with auto-renewal provisions.","Fifth Amended Section 382 Rights Agreement extends poison pill to November 13, 2026 to protect NOLs.","Rights Agreement purchase price set at $110.00 per one-thousandth of Series F Preferred Stock.","Rights Agreement requires shareholder approval at 2024 annual meeting; otherwise expires Nov 10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001224608-23-000067","json":"https://secwatch.observer/filing/0001224608-23-000067.json","markdown":"https://secwatch.observer/filing/0001224608-23-000067.md","text":"https://secwatch.observer/filing/0001224608-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1224608/000122460823000067/0001224608-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1224608/000122460823000067/cno-20231110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:39:32.090608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c76d22e604d86b8c93243ab8a2b8904f54d32231","claim":"CNO Financial Group, Inc.: Filing of Certificate of Designations for Series F Junior Participating Preferred Stock and Certificate of Elimination for Series E Junior Participating Preferred Stock in connection with amended rights agreement (effective 2023-11-13).","evidence_excerpt":"the Company will file with the office of the Secretary of State of the State of Delaware (i) on November 13, 2023 a Certificate of Designations (the “ Certificate of Designations ”) for the Series F Junior Participating Preferred Stock, par value $0.01 per share, of the Company relating to the Amended Rights Agreement, and (ii) on November 14, 2023 a Certificate of Elimination (the “ Certificate of Elimination ”) for the Series E Junior Participating Preferred Stock, par value $0.01 per share, of the Company relating to the Fourth Amended Rights Agreement.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1224608/000122460823000067/0001224608-23-000067-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}